Informed Consent for GLP-1 Medications: What Your Provider Must Tell You
Before you start semaglutide or tirzepatide, you have the right to understand exactly what you are agreeing to. Here is what true informed consent looks like for GLP-1 medications.
Informed consent is not a form you sign. It is a conversation where your provider gives you the information you need to make a genuinely autonomous decision about your healthcare. When it comes to semaglutide and tirzepatide, the stakes of that conversation are high because these are powerful medications with significant benefits and real risks.
Disclaimer
This article provides general information about informed consent and is not legal or medical advice. Standards for informed consent vary by state.
What Informed Consent Really Means
Legally and ethically, informed consent requires that you are given adequate information in understandable language about the proposed treatment, that you have the capacity to understand and evaluate that information, that your consent is voluntary and free from coercion, and that you are given the opportunity to ask questions and receive answers. A provider who hands you a form to sign without discussion has not obtained informed consent. A provider who describes only benefits without mentioning risks has not obtained informed consent. And a provider who pressures you to decide immediately has not obtained informed consent.
What Your Provider Should Tell You
Complete Informed Consent Includes
- How the medication works: GLP-1 receptor agonism, appetite reduction, slowed gastric emptying
- Expected benefits: Typical weight loss percentages, timeline, and variability
- Common side effects: Nausea, vomiting, diarrhea, constipation, headache (60-80% of patients)
- Serious risks: Pancreatitis, gallbladder disease, gastroparesis, thyroid cancer risk (in animal studies)
- Contraindications: Personal/family history of medullary thyroid carcinoma, MEN 2, active pancreatitis
- Drug interactions: Insulin, sulfonylureas, oral contraceptives, and other medications affected by slowed absorption
- What happens when you stop: Appetite returns, weight regain is common without lifestyle changes
- Alternatives: Other medications, surgical options, lifestyle-only approaches
- Compounded vs. brand: If receiving compounded medication, explanation of the differences
- Monitoring plan: What follow-up is planned and what symptoms should prompt immediate contact
Questions You Should Ask
Essential Questions for Your Provider
- What are the most serious risks I should watch for?
- How will you monitor me during treatment?
- What should I do if I experience severe nausea or abdominal pain?
- What is the plan for dose escalation?
- What happens if I want to stop the medication?
- Are there any conditions I have that increase my risk?
- How do my current medications interact with this one?
- If this is compounded, how is the quality assured?
- What is the expected timeline for results?
- What lifestyle changes should I make alongside medication?
Red Flags in the Consent Process
Be cautious if your provider rushes through the consent process without allowing questions, dismisses your concerns about side effects, guarantees specific results, does not ask about your medical history or current medications, does not mention any risks or contraindications, or pressures you to start immediately without time to consider. These behaviors suggest the consent process is being treated as a formality rather than a genuine patient protection.
Your Ongoing Rights
Informed consent is not a one-time event. You have the right to updated information as new risks or benefits become known, to ask questions at any point during treatment, to refuse dose increases or treatment changes, to withdraw consent and stop treatment at any time, and to seek a second opinion. A good provider welcomes your questions and concerns rather than treating them as obstacles.
The Bottom Line
Informed consent is your right and your protection. Before starting GLP-1 medication, ensure you understand the benefits, risks, alternatives, and monitoring plan. If your provider does not voluntarily provide this information, ask for it. And if they cannot or will not provide it, find a provider who will. Your health decisions should be informed, voluntary, and supported.
Transparent Care from Trimi
Thorough evaluations and honest informed consent. Semaglutide $99/mo, tirzepatide $125/mo.
Learn MoreMore on legal & regulatory
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication or treatment program.
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).